Does Dr. KEVIN ALEXANDER have financial conflicts of interest?

Dr. KEVIN ALEXANDER (MD) has received a total of $49,717 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $49,717 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. KEVIN ALEXANDER?

According to CMS Open Payments data, Dr. KEVIN ALEXANDER received funding from PFIZER ($12,874), NOVO NORDISK ($11,210), and ALNYLAM PHARMACEUTICALS ($10,264).

Does Dr. KEVIN ALEXANDER receive research grants or speaking fees?

Dr. KEVIN ALEXANDER has received $49,717 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. KEVIN ALEXANDER

MDReal-Time Hydrated

Specialty: Internal Medicine, Advanced Heart Failure and Transplant Cardiology

Practice Location: STANFORD, CA 94305

NPI Number: 1487953865

LIFETIME INDUSTRY VALUE

$49,717

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. ALEXANDER is a verified Internal Medicine, Advanced Heart Failure and Transplant Cardiology practitioner based in STANFORD, CA.

Between 2021 and 2024, Dr. ALEXANDER had an overall industry promotional and research financial footprint of $49,717 as recorded in the federal CMS Open Payments database.

$49,717 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. ALEXANDER's primary funding source is PFIZER, which accounts for $12,874 (representing 25.9% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

PFIZER

Rank 1

$12,874

25.9%

NOVO NORDISK

Rank 2

$11,210

22.5%

ALNYLAM PHARMACEUTICALS

Rank 3

$10,264

20.6%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.